The results of the SELECT cardiovascular outcomes trial, now published in full in the New England Journal of Medicine, confirm that semaglutide 2.4 mg weekly reduces the risk of major adverse cardiovascular events (MACE) by 26% in adults with obesity and pre-existing cardiovascular disease — even those without type 2 diabetes.

Trial Overview

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial enrolled 17,604 participants across 41 countries. All participants had a BMI ≥27, established cardiovascular disease, and no history of diabetes. They were randomized to weekly subcutaneous semaglutide 2.4 mg or placebo and followed for a mean of 39.8 months.

The primary composite endpoint — cardiovascular death, non-fatal heart attack, or non-fatal stroke — occurred in 6.5% of the semaglutide group versus 8.0% in the placebo group, representing a statistically significant 20% relative risk reduction (HR 0.80; 95% CI 0.72–0.90; P <0.001).

Beyond Weight Loss

Perhaps the most scientifically significant finding: cardiovascular benefit appeared independent of the degree of weight loss achieved. Even participants who lost less than 5% of body weight showed meaningful risk reduction, suggesting that GLP-1 receptor agonists exert direct cardioprotective effects — including anti-inflammatory, anti-atherosclerotic, and endothelial protective mechanisms — beyond their metabolic effects.

“SELECT has fundamentally changed how we should think about obesity treatment. This is not about aesthetics — it’s about preventing the next heart attack.”

— Dr. A. Michael Lincoff, Cleveland Clinic, principal investigator

Implications for Prescribing

Cardiologists and primary care physicians are now grappling with an expanded indication: semaglutide as a cardiovascular risk-reduction therapy in patients with obesity and established CVD, regardless of glycemic status. The American College of Cardiology is expected to update its obesity management guidelines to reflect these findings.

Safety and Side Effects

Gastrointestinal adverse events — nausea, vomiting, and diarrhea — were more common in the semaglutide group (44.9% vs 31.5%), particularly during dose escalation. Serious gastrointestinal events were rare. No increased risk of pancreatitis or diabetic retinopathy was observed.

The Supply Equation

The expanded indication places enormous pressure on global supply chains for semaglutide, which has already experienced chronic shortages driven by demand for weight management. Novo Nordisk has announced a $6.5 billion manufacturing expansion, but analysts warn that supply constraints will persist through at least 2027.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.